Enfusion shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight and lowered its price target from $11 to $9.

0.00% Pre

Enfusion, Inc.

ENFN

0.00

Enfusion shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight and lowered its price target from $11 to $9.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

How Vaxcyte's (PCVX) $1 Billion Thermo Fisher Deal Could Shape Its US Vaccine Supply Chain

Assessing Cabaletta Bio (CABA) Valuation as ESGCT Data Drives New Attention to Rese-cel Clinical Progress

Will Speculation Around U.S. Support Reshape TMC (TMC)’s Path to Critical Minerals Leadership?

Conekt.ai Collaboration Might Change The Case For Investing In Globalstar (GSAT)

Is There Still Opportunity in J&J Shares After 32% Rally in 2025?

New winners for the sixth week! Don't miss your chance to win 18,888 riyals or an iPhone 17 Pro Max.

JP Morgan Maintains Overweight on Nucor, Raises Price Target to $172

Pre-Bell Movers | ELAB Ascends Markedly by 203.1%; Here Are 20 Stocks Moving Premarket